Drug development in oncology is undergoing several changes brought about by precision medicine, which makes it appealing to move efficacy assessment to earlier-phase trials and questions the need for randomized trials. Indeed, some remarkably efficacious drugs have even been approved based on uncontrolled phase I or II trials. With very few exceptions, we challenge the […]

Introducing the new single-use separator, Alfa Laval CultureOne™ From greater flexibility to shorten the time to market, to increased assurance of patient safety, several factors have driven the growing transition to single-use processing in the biopharma industry. More manufacturers are seeking solutions that enable smaller batches and predictable, scalable production. Of course, this requires compact […]

Implementing and Validating Meso Scale Discovery – ECL Detection for Clinical Trials When implementing biomarker strategies for clinical trials, it is not only important to choose the right analysis platform but also have the assays validated and performed to meet regulatory submission requirements. Unilabs Serving Pharma group, in collaboration with Meso-Scale Discovery (MSD) will present […]

The success of several drugs in amorphous systems in the commercial market confirm that amorphous drug delivery system is one the efficient ways of enhancing solubility and optimizing bioavailability of poorly soluble drugs. Spray drying and hot melt extrusion are the two technologies most widely used for the preparation of amorphous solid dispersion. In addition, […]

Keep up with transparency trends and leverage disclosure data for patient engagement and recruitment While the complexity and costs of clinical trial transparency regulations continue to increase, there are growing opportunities to leverage investments in disclosure compliance. Understanding the requirements and trends helps identify opportunities to reuse the disclosure data beyond submissions to regulatory authorities […]

The 7 most important things to update in your technical documentation and your QMS, and how they interact Do you want to understand which parts of the MDR that you as medical device manufacturer must have in place on May 26th and what you need to adjust in your technical documentation, when CE-marking a device […]

Biopharmaceutical products in development continue to increase in complexity, which effects how companies choose to express proteins and eventually, manufacture at clinical and commercial scale. In this webinar, co-organized by Medicon Valley Alliance and Catalent, experts from Catalent Biologics and Sartorius will discuss new cell line development methodologies, including new instrumentation, which are enabling complex […]

Welcome to Medicon Valley Alliance Good Morning Meeting with IQVIA on: Value creation in a changing world: Optimising clinical trial success through a purposeful use of data and technology With over 4,000 assets in clinical development, developing medical innovation that can truly stand out has become increasingly more challenging for biotech players. Designing a compelling […]

Welcome to Medicon Valley Alliance Good Morning Meeting with Syneos Health on: Using a ‘virtual pharma model’ to attract targeted investors for biotech innovators De-risk investment, de-risk operational delivery and maximize the return on investment (ROI) for all parties How to position your organization for fundraising using a virtual pharma partner model – Using the […]

Welcome to Medicon Valley Alliance Good Morning Meeting on “Cancer immunotherapies – Preparing for a successful clinical program” with KLIFO. Recent advances in immuno-oncology have shown great promise for effective and safer treatments. Best examples are the check point inhibitors which are moving towards first line treatment in various cancer types. Currently, numerous drug modalities […]

Welcome to MVA’s Good Morning Meeting on “Biomarkers analysis challenges in Clinical Trials” with HalioDx. One of the biggest challenges in immunotherapy area is to find accurately which patients will benefit from a therapy or a combination of therapies. To help drug developers getting this information, the assessment of biomarkers through clinical research studies represent […]

Ökad samverkan över sundet, Köpenhamn & Malmö Medeon Science Park & MVA Medicon Valley Alliance bjuder in till frukostmöte. Varmt välkomna till ett frukostmöte där ni möter Medeons CEO Ulf Andersson som kommer att berätta om Medeons strategi 2016 och tankar på närmare samverkan över sundet och nya former för samarbeten med akademin. Ni får […]

Requirements for cell based assays have induced a rapid development of novel cell models. To improve the effectiveness of target research and compound development the use of patient or stem cell-derived cell models is becoming increasingly important. SIRION Biotech specializes in viral vector technology and provides sophisticated cell…

The first Good Morning Ambassador Meeting in 2013 will focus on eHealth solutions and status of telemedicine in two highly interesting countries, Japan and South Korea. Note that this event will be held in Sweden 25 February and in Denmark 26 February!

The first Good Morning Ambassador Meeting in 2013 will focus on eHealth solutions and status of telemedicine in two highly interesting countries, Japan and South Korea. Note that this event will be held in Sweden 25 February and in Denmark 26 February!

As the size and complexity of large scientific datasets increases, life sciences teams from industry and academic are using cloud computing to deliver results more quickly, at larger scale and more cost effectively. Medicon Valley Alliance in collaboration with Amazon Web Services is excited to invite you to a morning of lively discussion…

Patents are challenged during examination, opposition, and invalidity proceedings and are subjected to scrutiny during due diligence. Patent authorities and competitors try to break through the defenses. Licensees use any weakness in the patents to lower the price. Only the good patents survive. Learn from the patent experts of Høiberg how to distinguish good from […]

Patents are challenged during examination, opposition, and invalidity proceedings and are subjected to scrutiny during due diligence. Patent authorities and competitors try to break through the defenses. Licensees use any weakness in the patents to lower the price. Only the good patents survive. Learn from the patent experts of Høiberg how to distinguish good from […]

IPR rules and issues in relation to the Korean market – is patenting different in Korea, compared to Europe and USA? Yes – there are differences in legislation and practices in addition to cultural differences, which together may lead to a different outcome in the patent application process in Korea compared to Europe or America. […]